[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-carcinoma":568},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,47,59,93,123,143,169,193,213,240,258,277,299,318,336,352,369,396,417,434,453,492,513,532,550],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054018",false,"NCT07619534","Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases","Sample Collection Study to Analyze Cerebral Spinal Fluid as a Biomarker for Brain Metastasis in Metastatic Breast Cancer","* INCLUSION CRITERIA:\n* Pathology documentation of histologically confirmed HER2+ BC or TNBC with a history of metastatic disease.\n* Participants must be able to undergo lumbar puncture (LP) and brain MRI.\n* Women age \\>= 18 years\n* Adequate organ function as defined below:\n\n  * Creatinine \\\u003C=1.5 x institutional upper limit of normal (ULN)\n\nOR\n\n--Calculated Creatinine clearance \\>=40 mL\u002Fmin\u002F1.73 m2 for individuals with creatinine levels above institutional ULN (using either Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n\n\\- Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Prior history or current MRI-detected brain metastasis or leptomeningeal disease\n* Previous history of any invasive malignancies, except for surgically resected local cutaneous malignancies.\n* Pregnancy","ALL","18 Years","120 Years",{"count":20,"type":21},139,"ESTIMATED","OBSERVATIONAL","Background:\n\nBreast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal. Researchers want to know if tumor DNA found in spinal fluid, blood, or tumor tissue can help predict when the cancer will spread to the brain. They want to collect these fluid and tissue samples for research.\n\nObjective:\n\nTo collect spinal fluid and other samples from people with breast cancer that has spread to other parts of the body.\n\nEligibility:\n\nPeople aged 18 years and older with HER2-positive or triple negative breast cancer. The cancer must have spread to other parts of the body but not to the brain.\n\nDesign:\n\nParticipants will be screened. They will have blood tests to assess kidney function. They will have an imaging scan of the brain.\n\nParticipants will come to the NIH clinic to have their samples collected:\n\n* Spinal fluid. A thin needle will be inserted into the lower back to draw out a sample of fluid from the space around the spinal cord. A physical exam and blood tests will be done to make sure it is safe for participants to have this procedure.\n* Blood.\n* Saliva or cheek swabs. They will rub a cotton swab inside of their mouth.\n* Tumor samples. If participants have had samples of tumor tissue (biopsies) collected in the past, leftover tissue may be used for this study.\n\nParticipants will be contacted for follow-up every 6 months for 3 years. They may return once a year to provide further samples....",[25,26,27,28],"Breast Cancer","Breast Carcinoma","Cancer of the Breast","Malignant Neoplasm of Breast",[30,31,32,33],"Triple Negative Breast Cancer (TNBC)","HER2-Postitive","Metastatic Breast Cancer","Cerebral Spinal Fluid Collection","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":21},"2026-07-16",{"date":42,"type":21},"2034-07-01",{"name":44,"class":45},"National Cancer Institute (NCI)","NIH",1,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":50,"keywords":51,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":46},"100638410",{"count":20,"type":21},[25,26,27,28],[30,31,32,33],"2026-07-01",{"date":54,"type":38},"2026-07-02",{"date":56,"type":21},"2026-07-07",{"date":42,"type":21},{"name":44,"class":45},{"id":60,"slug":4,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":16,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100592628","NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year",true,"45 Years","75 Years",{"count":68,"type":21},24000,"INTERVENTIONAL",[71],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[74,26,75,76,77,78,79,80,81,82,83],"Bladder Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma","RECRUITING","2026-06-30",{"date":52,"type":38},{"date":88,"type":38},"2025-06-18",{"date":90,"type":21},"2029-06-30",{"name":44,"class":45},38,{"id":94,"slug":4,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":69,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100494339","NCT05716893","Study of Aerobic Training for People Receiving Treatment for Breast Cancer","Phase 2 Trial of Adaptive Versus Standard Dosing of Aerobic Training in Patients Receiving Treatment for Primary Breast Cancer","Inclusion Criteria:\n\n* Aged ≥18 years\n* Female\n* Diagnosed with primary breast cancer as defined by one of the following:\n\n  * Histological confirmation\n  * As per standard of care imaging\n* Scheduled to receive neoadjuvant\u002Fadjuvant systemic and\u002For locoregional therapy\n* Performing ≤90 minutes of moderate- and\u002For strenuous-intensity exercise per week, as evaluated by self-report\n* Willingness to comply with all study-related procedures\n* Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:\n\n  1. Achieving a plateau in oxygen consumption, concurrent with an increase in power output;\n  2. A respiratory exchange ratio ≥ 1.10;\n  3. Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax \\[HRmax = 220-Age\\[years\\]);\n  4. Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.\n\nExclusion Criteria:\n\n* Enrollment onto any other interventional investigational study, except interventions determined by the PI not to confound study outcomes\n* Receiving treatment for any other diagnosis of invasive cancer\n* Distant metastatic malignancy of any kind\n* Mental impairment leading to inability to cooperate\n* Any of the following contraindications to cardiopulmonary exercise testing:\n\n  i. Acute myocardial infarction within 3-5 days of any planned study procedures; ii. Unstable angina; iii. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise; iv. Recurrent syncope; v. Active endocarditis; vi. Acute myocarditis or pericarditis; vii. Symptomatic severe aortic stenosis; viii. Uncontrolled heart failure; ix. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures; x. Thrombosis of lower extremities; xi. Suspected dissecting aneurysm; xii. Uncontrolled asthma; xiii. Pulmonary edema; xiv. Respiratory failure; xv. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis) xvi. Room air desaturation at rest ≤ 85%\n* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation","FEMALE",{"count":101,"type":21},140,[103],"PHASE2","In this study, investigators will compare standard Aerobic Training\u002FAT with adaptive Aerobic Training\u002FAT. Standard AT will be a fixed (unchanging) amount of walking each week, while adaptive AT will adjust the level of exercise depending on participants' response to the exercise. Investigators will see how both study approaches (standard AT and adaptive AT) affect participants' CRF.",[25,26],[107,108,109,110,111,112],"Breast cancer","Breast carcinoma","Primary breast cancer","Aerobic Training","22-364","Memorial Sloan Kettering Cancer Center","2026-06-24",{"date":115,"type":38},"2026-06-29",{"date":117,"type":38},"2023-01-30",{"date":119,"type":21},"2028-01-30",{"name":112,"class":121},"OTHER",7,{"id":124,"slug":4,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":69,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":4},"100644613","NCT07671690","Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data","Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data: A Multicenter Retrospective and Prospective Validation","Inclusion Criteria:\n\n1. Histopathologically confirmed invasive breast cancer;\n2. Planned to receive a full course of neoadjuvant therapy;\n3. Complete baseline imaging data (MRI\u002Fultrasound\u002Fmammography) and core needle pathology results available.\n\nExclusion Criteria:\n\n1. Previous history of ipsilateral breast cancer or chest radiotherapy;\n2. Distant metastasis (Stage IV);\n3. Poor image quality or missing clinical data exceeding 20%.","80 Years",{"count":131,"type":21},1800,[71],"This study aims to develop a multimodal deep learning model integrating MRI, ultrasound, digital pathology and clinical information based on multicenter retrospective data. To externally validate the model in an independent prospective cohort, and evaluate its accuracy in predicting pathological complete response (pCR), 3-year and 5-year disease-free survival (DFS). To establish visual tools such as nomograms, assisting clinicians in identifying patients with chemoresistance and facilitating individualized de-escalation or escalation treatment strategies.",[26],"2026-06-22",{"date":137,"type":38},"2026-06-26",{"date":139,"type":21},"2026-06-01",{"date":90,"type":21},{"name":142,"class":121},"Yunnan Cancer Hospital",{"id":144,"slug":4,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":69,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100530282","NCT06184750","Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial","Inclusion Criteria:\n\n* Premenopausal women at the time of enrollment defined by any of the following:\n\n  * Age under 50 years and regular menstruation (most recent period within the past 3 months)\n  * Age under 50 years and continuous hormonal contraception use and at least one intact ovary\n  * Women who are not postmenopausal based on serum hormone levels. Women with estradiol =\\\u003C 30 pg\u002FmL, follicle-stimulating hormone (FSH) \\>= 30 IU\u002FmL are eligible\n* Women with any of the following:\n\n  * A history of unilateral estrogen receptor (ER) positive ductal carcinoma in situ (DCIS) with local therapy completed (as determined by treating physician recommendation and patient acceptance) at least 1 month prior to study entry. (The untreated breast will be the study breast, for both imaging and optional biopsy)\n  * Recent or prior lobular carcinoma in situ (LCIS), or any form of epithelial atypia, flat epithelial (FEA), atypical ductal hyperplasia (ADH), or atypical lobular hyperplasia (ALH)\n  * Are risk eligible for preventive medication based on a five-year risk of 1.7% or greater, estimated with a validated model: the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool, Tyrer-Cusick, Breast Cancer Surveillance Consortium. If the Tyrer-Cuzick model is used a ten-year risk of 3.4% or greater is acceptable\n  * Are tamoxifen-eligible by American Society of Clinical Oncology (ASCO) guidelines (\\>= 2-fold increased risk compared to peer if age \\>= 45 years, and \\>= 4-fold increased risk if age \\\u003C 45 years)\n  * A history of mantle radiotherapy\n  * A moderate penetrance germline pathogenic variant\n* Participants ≥ 18 and ≤ 55 years old will be enrolled. Our trial objectives are not relevant to females under 18 years of age since breast cancer is extraordinarily rare in this age group, and there are no guidelines regarding use of tamoxifen in children, even if know to be at very high risk for breast cancer when older. Because no dosing or adverse event (AE) data are currently available on the use of tamoxifen in participants \\\u003C 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status must be =\\\u003C 2 (Karnofsky \\>= 60%)\n* Human immunodeficiency virus (HIV)-infected patients are eligible to participate if they are on effective anti-retroviral therapy with undetectable viral load within the prior 6 months\n* Women with evidence of chronic hepatitis B virus (HBV) infection, are also eligible if the HBV viral load is undetectable; they may be on suppressive therapy, if indicated\n* Women with a history of hepatitis C virus (HCV) infection are eligible if treated and cured. For those who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Women with herpes simplex virus (HSV) infection are eligible if on chronic or as needed (due to a flare) suppressive antiviral therapy\n* Hormonal contraceptive users are eligible and should maintain the same oral contraceptive preparation throughout the duration of the trial. For women who have a levonorgestrel-coated intra-uterine device, removal for medical reasons will be allowed\n* The effects of tamoxifen on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because tamoxifen is known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* Breast Imaging Reporting and Data System (BIRAD) 1 or 2. If BIRAD 0, follow-up diagnostic imaging must be BIRAD 1 or 2 or cleared clinically with radiology recommendation of return to annual screening\n* Women who are factor V leiden carriers and have not had a blood clot are eligible, if approved by their treating physician\n\nExclusion Criteria:\n\n* BIRADS breast density category A on most recent mammogram\n* History of selective estrogen receptor modulator (SERM) use within the past 5 years unless:\n\n  * Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment OR\n  * Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment\n* History of invasive breast cancer\n* Prior bilateral mastectomy or breast augmentation surgery including breast implants. Prior bilateral excisional surgical biopsy, mastopexy (breast lift) or mammoplasty (breast reduction) is allowed, as long as \\> 1 year has passed since the procedure\n* Women with \"mosaic mammographic screening views\", i.e., whose larger breast size precludes being imaged within a single mammographic screening view\n* Current use of a strong CYP3A4 inducer or a strong CYP2D6 inhibitor unless willing and able to discontinue use and switch to an alternative medication for the duration of participation, under the advice of their physician. If the physician believes the current medication cannot be replaced, the participant will not be eligible\n* Current use of Warfarin\n* Planning to become pregnant within the next two years. Potential study participants will be questioned about this and excluded if they are planning pregnancy over the next 20 months\n* History of thromboembolism, pulmonary embolism, thrombotic stroke, arterial thrombosis of the extremity or deep vein thrombosis. A history of superficial thrombophlebitis is allowed\n* History of uterine cancer or atypical uterine hyperplasia with uterus intact\n* Participants may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen\n* Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study because tamoxifen a category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with tamoxifen. Breastfeeding should be discontinued if the mother is treated with tamoxifen\n* Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1\u002F2, CDH1, PALB2, PTEN, STK11, or P53\n* Current use of sex hormones (estrogen, progesterone, or androgens), unless part of oral contraception pills\n* Prior invasive cancer, unless curatively treated, and all treatment was completed \\> 5 years prior to enrollment","55 Years",{"count":151,"type":21},200,[103],"This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.",[155,156,26,157,158,159],"Breast Atypical Ductal Hyperplasia","Breast Atypical Lobular Hyperplasia","Breast Ductal Carcinoma In Situ","Breast Lobular Carcinoma In Situ","Estrogen Receptor-Positive Breast Carcinoma","2026-06-16",{"date":162,"type":38},"2026-06-17",{"date":164,"type":38},"2024-09-27",{"date":166,"type":21},"2028-09-30",{"name":44,"class":45},11,{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":69,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":192},"100524736","NCT06112613","Mobile Health for Adherence in Breast Cancer Patients","Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)","Inclusion Criteria:\n\n* NON-PATIENT: Participants must be an oncology healthcare provider (i.e., oncologist, advanced practice provider, or oncology nurse)\n* NON-PATIENT: Participants must have taken care of at least one patient randomized to Arm B (CONCURxP) who had less than 85% adherence rate at 12 months as measured by the WiseBag\n* NON-PATIENT: Participant must speak English\n* NON-PATIENT: Participant must be employed at an National Cancer Institute Community Oncology Research Program (NCORP) site for at least 6 months\n* NON-PATIENT: Participant must be able to provide informed consent to participate in this study\n* PATIENT STEP 0: Patient must be \\>= 18 years of age\n* PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish\n* PATIENT STEP 0: Patient must present with new or established pathologically proven hormone receptor (HR)+ HER2- metastatic breast cancer at the time of Step 0\n* PATIENT STEP 0: Patient must have initiated any of the CKD4\u002F6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30 days prior to consenting to Step 0 or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent\n\n  * NOTE: Patients who have been treated previously with anticancer treatments other than CDK4\u002F6 inhibitors are eligible\n  * NOTE: CDK4\u002F6 inhibitors must be provided\u002Fsupplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible\n  * NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4\u002F6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order\n* PATIENT STEP 0: Patients must not have been previously treated with any of the following CDK4\u002F6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio\n* PATIENT STEP 0: Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4\u002F6 inhibitors\n* PATIENT STEP 0: Patient must confirm that they intend to receive their care or monitoring at an NCORP site\n* PATIENT STEP 0: Patient must have a personal mobile phone in which they are able and willing to send and receive text messages\n\n  * NOTE: The restriction to those with mobile phone access with text messaging is based on the primary intention of the study which involves the use of text messaging to improve adherence\n* PATIENT STEP 0: Patient must have an email address\n\n  * NOTE: The restriction to those with an email address is based on the primary intention of the study which involves patients responding to questions regarding their reasons for non-adherence after every missed dose to improve adherence\n* PATIENT STEP 0: Patient must have the ability to understand and the willingness to sign a written informed consent document\n\n  * NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available are not eligible\n* PATIENT STEP 0: Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status \\>= 3 OR patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)\n* PATIENT STEP 0: Patient must not be enrolled in other trials offering financial assistance\n\n  * NOTE: Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance\n* PATIENT STEP 1: Patient must meet all the eligibility criteria for Step 0\n* PATIENT STEP 1: Patient must have signed a written informed consent form\n* PATIENT STEP 1: Patient must have completed baseline survey within 30 days of the date of Step 0 Registration\n* PATIENT STEP 1: Patients must have initiated their CDK 4\u002F6 inhibitors within 30 days of the date of Step 0 registration",{"count":176,"type":21},410,[71],"This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4\u002F6 inhibitor. To ensure CDK4\u002F6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4\u002F6 inhibitor.",[180,26,181,182],"Anatomic Stage IV Breast Cancer AJCC v8","HER2-Negative Breast Carcinoma","Hormone Receptor-Positive Breast Carcinoma",{"date":184,"type":38},"2026-06-18",{"date":186,"type":38},"2024-01-26",{"date":188,"type":21},"2027-07-31",{"name":190,"class":191},"ECOG-ACRIN Cancer Research Group","NETWORK",506,{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":64,"sex":99,"minAge":17,"maxAge":65,"enrollmentInfo":199,"targetDuration":4,"studyType":69,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100482119","NCT05557877","Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer","Targeted Prevention of Postpartum-Related Breast Cancer","Inclusion Criteria:\n\n* PRE-REGISTRATION: Age \\>= 18 years and =\\\u003C 45 years of age\n* PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research at two timepoints.\n* PRE-REGISTRATION: Had a live birth =\\\u003C 10 years prior to pre-registration\n* PRE-REGISTRATION: Pre-menopausal according to patient report and\u002For clinical determination\n* PRE-REGISTRATION: Provide written informed consent\n* PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance\n* PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research\n* REGISTRATION: Age \\>= 18 years and =\\\u003C 45 years of age\n* REGISTRATION: Registration for this study must be completed either =\\\u003C one (1) year after the qualifying pre-registration biopsy is performed for this study or =\\\u003C one (1) year after collection of the archived tissue (for those who did not have a pre-registration biopsy performed after pre-registration for this study)\n* REGISTRATION: Hemoglobin \\>= 9.0 g\u002FdL (obtained =\\\u003C 90 days prior to registration)\n* REGISTRATION: Platelet count \\>= 100,000\u002Fmm\\^3 (obtained =\\\u003C 90 days prior to registration\n* REGISTRATION: Serum creatinine =\\\u003C 2.0 mg\u002Fdl (obtained =\\\u003C 90 days prior to registration)\n* REGISTRATION: Negative pregnancy test done =\\\u003C 15 days prior to registration\n* REGISTRATION: Willing to use contraception while on treatment\n* REGISTRATION: Provide written informed consent\n* REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance\n* REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research\n* REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research\n* REGISTRATION: Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n\nExclusion Criteria:\n\n* PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS)\n* PRE-REGISTRATION: Received systemic treatment for any other cancer at any time\n* PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =\\\u003C 5 days prior to pre-registration and no more than four doses within =\\\u003C 30 days prior to pre-registration)\n* PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer\n* PRE-REGISTRATION: Currently taking anticoagulants\n* PRE-REGISTRATION: Contraindication for aspirin use\n* PRE-REGISTRATION: Known or suspected active breast infection\n* REGISTRATION: Known DCIS or invasive cancer\n* REGISTRATION: No research tissue available from pre-registration biopsy or from archived tissue (collected =\\\u003C 12 months prior to pre-registration)\n* REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =\\\u003C 5 days prior to registration and no more than four doses within =\\\u003C 30 days prior to registration)\n* REGISTRATION: Co-morbid illnesses\u002Fconditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* REGISTRATION: Any contraindication to aspirin use including but not limited to:\n\n  * Bleeding disorders (e.g., hemophilia)\n  * Stomach or intestinal bleeding =\\\u003C 6 months prior to registration\n  * Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs)\n* REGISTRATION: Currently taking anticoagulants\n* REGISTRATION: Any prior or current malignancy requiring prior or current systemic therapy\n* REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days\n* REGISTRATION: Post-menopausal:\n\n  * Prior bilateral surgical oophorectomy or\n  * No menses for \\> 1 year with estradiol levels within postmenopausal range, according to institutional standard\n* REGISTRATION: Known or suspected active breast infection",{"count":200,"type":21},60,[103],"This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.",[26],"2026-06-15",{"date":160,"type":38},{"date":207,"type":38},"2023-03-09",{"date":209,"type":21},"2027-01-30",{"name":211,"class":121},"Mayo Clinic",5,{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":69,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100629393","NCT07474090","Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial","Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)","STEPS-BC","Inclusion Criteria:\n\n* Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent \\[if prior treatment received ≥ 2 years prior\\] but not metastatic breast cancer being treated with curative intent). All molecular subtypes (estrogen receptor \\[ER\\], progesterone receptor \\[PR\\], human epidermal growth factor receptor 2 \\[HER2\\], etc.) are acceptable\n* Scheduled to receive neoadjuvant or adjuvant cytotoxic chemotherapy. Patient must be enrolled ≤ 3 weeks from start of cytotoxic chemotherapy\n* Age 18 to 85 years at enrollment. The upper age cut-off is due to the increased risk of injury in the older population during the CPET, which uses stationary bicycle exercise testing, outweighing the benefit of including this age group\n* Must be able to complete a stationary bicycle exercise test where you pedal against some resistance on a stationary bike with supervisors at your side per patient self-report\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting per patient self-report\n* Able to hold breath for 8 seconds\n* Must be able to read and understand English language\n* Must have access to a device that allows teleconferencing (e.g., Zoom calls) or be willing to participate in the Tablet Lending Program\n* Must be willing to download and use the Trainerize application to their personal device or be willing to participate in the Tablet Lending Program\n* Must have a working email address to participate in teleconferencing (e.g., Zoom calls). Local National Cancer Institute Community Oncology Research Program (NCORP) site staff may assist in setting up a new email address, if needed\n\nExclusion Criteria:\n\n* At enrollment, the following diagnosis and\u002For conditions may not be present (i.e., documented in the medical record or by patient self-report):\n\n  * Symptomatic claustrophobia\n  * Pregnancy or breast-feeding\n  * Ferromagnetic cerebral aneurysm clips or other intraorbital\u002Fintracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices, such as tissue expanders\n  * Uncontrolled hypertension (systolic blood pressure \\> 190 mm Hg or diastolic blood pressure \\> 100 mm Hg)\n  * Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion, as determined by the treating physician\n  * Significant ventricular arrhythmias (\\> 20 premature ventricular contractions \\[PVCs\\]\u002Fmin)\n  * Atrial fibrillation with uncontrolled ventricular response (\\> 130 beats per minute \\[bpm\\])\n  * Unstable or stable angina (cardiac chest pain)\n  * Severe pulmonary hypertension\n  * Left main coronary artery disease\n  * Symptomatic heart failure\n  * Severe valvular heart disease\n  * Aortic aneurysm (\\> 45 mm diameter) or aortic dissection\n  * Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise\n  * Hypertrophic obstructive cardiomyopathy\n* Acute myocardial infarction within 28 days of enrollment\n* Acute pulmonary embolus and\u002For deep vein thrombosis within 24 weeks prior to enrollment\n* Plans to relocate within 6 months of enrollment and unable to participate in study procedures\n* May not be on a simultaneous interventional supportive care (non-therapeutic) clinical trial\n* May not be undergoing simultaneous treatment for a concurrent second primary cancer (patients with historical cancer will not be excluded if chemotherapy was received ≥ 2 years prior)\n* May not be currently engaged in ≥ 300 minutes of moderate to vigorous intensity physical activity per week as determined by self-report on the International Physical Activity Questionnaire -Short Form (IPAQ-SF). Site should use the IPAQ-SF screener in the REDCap WF-2401 STEPS-BC screening project to assist in this determination","85 Years",{"count":222,"type":21},120,[71],"This clinical trial studies whether a healthy living intervention (HLI), with or without a physical activity intervention (PAI), helps maintain the ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment. Early detection and enhanced therapies for breast cancer have improved 5-year cancer-related survival rates. Unfortunately, many breast cancer survivors are at high risk for long-term exercise intolerance, decreased heart health, and lower quality of life following chemotherapy. Currently, there are no effective therapies to help patients maintain these areas throughout chemotherapy. The HLI in this study includes virtual health education classes, which provide useful information on topics like proper nutrition, managing stress, and sleep practices. This may help patients understand the importance of living a healthy lifestyle during chemotherapy. The PAI in this study consists of virtual exercise sessions personalized to the needs of the patient, which may make it easier for patients to stay active during chemotherapy. HLI with PAI may be a more effective way to help maintain ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment.",[226,227,228,26,229,230],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Breast Inflammatory Carcinoma","Locally Recurrent Breast Carcinoma","2026-06-12",{"date":204,"type":38},{"date":234,"type":38},"2026-05-27",{"date":236,"type":21},"2030-04-30",{"name":238,"class":121},"Wake Forest University Health Sciences",2,{"id":241,"slug":4,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":69,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":46},"100493371","NCT05704283","3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer","3D Ultrasound Imaging of the Axillary Lymph Nodes","Inclusion Criteria:\n\n* Patients with lymph node biopsy or lymph node clip placement as per routine clinical care.\n* Age of 18 or older.\n\nExclusion Criteria:\n\n* Vulnerable subjects such as prisoners and adults lacking capacity to consent.",{"count":247,"type":21},55,[249],"EARLY_PHASE1","This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in evaluating lymph nodes in patients with breast cancer. Ultrasound uses high-frequency sound waves to generate images of the body.",[26],{"date":204,"type":38},{"date":254,"type":38},"2023-02-14",{"date":256,"type":21},"2027-06-01",{"name":211,"class":121},{"id":259,"slug":4,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":46},"100452975","NCT05178498","Impact of Dietary Inflammatory Potential on Breast Cancer Risk","Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Established in the high risk clinic at OSUCCC- James (includes patients with family history of breast cancer \\[BC\\], known genetic predisposition, personal history of known atypia\u002Fbreast lobular carcinoma in situ \\[LCIS\\], or prior chest wall radiation)\n* Patients at high risk for BC established in the surgical oncology clinic at Stefanie Spielman Comprehensive Breast Center (SSCBC), with one of the following diagnoses: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), sclerosing adenosis (SA), or radial scars (RS)\n* Able to read and understand English\n* Able to provide informed consent\n* Must consent to continued follow-up of medical records during the study period\n\nExclusion Criteria:\n\n* Prisoners\n* Not able to speak and understand English\n* Known personal history of ductal carcinoma in situ (DCIS) or Invasive BC",{"count":265,"type":21},960,"This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.",[155,156,26,158,268],"Breast Sclerosing Adenosis","2026-06-10",{"date":231,"type":38},{"date":272,"type":38},"2023-10-25",{"date":274,"type":21},"2035-12-31",{"name":276,"class":121},"Ohio State University Comprehensive Cancer Center",{"id":278,"slug":4,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":46},"100132279","NCT00991094","Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults","Inclusion Criteria:\n\n* All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol\n* Patients must sign a study-specific consent form prior to study entry\n\nExclusion Criteria:\n\n* Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site",{"count":284,"type":21},5000,"This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.",[26,76,287,288,289,79,290,291,80],"Genitourinary System Carcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Central Nervous System Neoplasm","Malignant Digestive System Neoplasm",{"date":231,"type":38},{"date":294,"type":38},"2005-05-27",{"date":296,"type":21},"2027-12-31",{"name":298,"class":121},"M.D. Anderson Cancer Center",{"id":300,"slug":4,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":99,"minAge":305,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":69,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":46},"100642341","NCT07644702","WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income Women","A Community Engagement Approach to Increasing Breast Cancer Screening and Clinical Trial Participation in Low Income and Rural Populations ('WE-CARE')","Inclusion Criteria:\n\n* Female\n* Be between the ages of 50 and 74 years\n* Have no prior history of breast cancer screening (i.e., who have either never received a mammogram or have not had one in the past five years)\n* Reside in a rural community in Wisconsin or belong to low income (self-reported)\n* Be able to speak and understand English or Spanish\n* Be willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Women who have received a mammogram within the past five years\n* Have a current or prior diagnosis of breast cancer\n* Are currently undergoing treatment for any active malignancy\n* Have cognitive or psychiatric impairments that, in the judgment of the study team, would preclude meaningful participation","50 Years","74 Years",{"count":308,"type":21},50,[71],"This clinical trial tests how well the Women's Engagement for Cancer Awareness, Resources, and Education (WE-CARE) community health forums work to increase breast cancer screening and clinical trial participation for rural and low income women. Despite advances in breast cancer diagnosis and treatment in the past decade, rural-dwelling and underserved women, and Black, Indigenous, and people of color continue to experience low rates of breast cancer screening. Since the survival rate for breast cancer is largely dependent on stage at which it is diagnosed, later stage breast cancer is correlated to a poorer prognosis and higher mortality rate. The WE-CARE community health forms address structural barriers through culturally tailored educational sessions on breast cancer risk, screening and clinical trials, survivor storytelling to humanize cancer and research and patient navigation to facilitate mammogram screening and address barriers. The WE-CARE community health forums may be an effective way to increase breast cancer screening and clinical trial participation for rural and low income women.",[26],"2026-06-08",{"date":231,"type":38},{"date":315,"type":38},"2026-01-05",{"date":119,"type":21},{"name":211,"class":121},{"id":319,"slug":4,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":64,"sex":99,"minAge":323,"maxAge":66,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":239},"100598796","NCT07076147","Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer","Inclusion Criteria:\n\n* \\* \\>= 30 years\n\n  * =\\\u003C 75 years\n  * Women with either:\n\n    * Genetic test results showing moderately increased breast cancer risk due to a pathogenic\u002Flikely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR\n    * Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)\n  * Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago\n  * Women recommended to undergo annual breast MRI and\u002For annual mammogram beginning at the time of their genetic counseling risk assessment\n  * English or Spanish speaking patients\n\nExclusion Criteria:\n\n* \\* History of breast cancer before genetic counseling at University of Southern California (USC)\n\n  * Any metastatic cancer diagnosis at time of genetic counseling risk assessment\n  * Deceased\n  * Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment","30 Years",{"count":325,"type":21},150,"This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.",[26],"2026-05-29",{"date":139,"type":38},{"date":331,"type":38},"2025-06-02",{"date":333,"type":21},"2028-06-02",{"name":335,"class":121},"University of Southern California",{"id":337,"slug":4,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":46},"100576275","NCT06783179","Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement","Postoperative Outcomes and Patient Satisfaction for Patients Admitted to the Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement","Inclusion Criteria:\n\n* Women who underwent mastectomy followed by tissue expander reconstruction for breast cancer or high-risk gene mutation prophylaxis followed by immediate tissue expander reconstruction who are either admitted to the Care Hotel post operatively, discharge home or admitted to the hospital.\n\nExclusion Criteria:\n\n* Younger than 18 years old.",{"count":325,"type":21},"This study evaluates the postoperative outcomes of patients who are admitted to the Mayo Clinic Florida Care Hotel after mastectomy and tissue expander placement. At Mayo Clinic Florida, patients receiving low risk surgeries are often admitted to the hospital overnight for observation. A new model of delivering patient care was created at the Mayo Clinic Florida coined the \"Care Hotel.\" This is a temporal, voluntary accommodation that offers patients a comfortable environment to receive nursing care before or after hospital treatment with in-person daytime monitoring and 24-hour virtual tele-monitoring in a hotel setting. This study evaluates post operative complications in patients who underwent mastectomy followed by tissue expander reconstruction and were admitted to the Care Hotel for overnight observation compared to the standard hospital admission and those who are discharged home.",[26],{"date":346,"type":38},"2026-06-02",{"date":348,"type":38},"2024-12-16",{"date":350,"type":21},"2027-12-16",{"name":211,"class":121},{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":129,"enrollmentInfo":358,"targetDuration":4,"studyType":69,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":46},"100537146","NCT06274034","MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors","Pilot Study of a Wearable EEG Headband as a Meditation Device for Breast Cancer Survivors","Inclusion Criteria:\n\n* Age between 18-80\n* Breast cancer first diagnosed with stage 1-4 breast cancer in the past 10 years\n* Patients report experiencing anxiety and insomnia both rated \\> 3 on a 0-10 scale (with 0 indicating none) at the time of enrollment\n* Patients on anti-anxiety\u002Fanti-depressant medication must be on stable dose for 1 month prior to study enrollment and must stay on that same dose throughout the trial\n* Has smart phone or tablet\n* Patient willing to use Google-based anonymous email account to sign up for MUSE\n* Be willing to provide informed consent and complete all aspects of the study\n* Have no contraindicating comorbid health condition which would interfere with the proper use of the Muse-S (trademark) system, as determined by the clinical investigators\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Individuals who have used a regular mindfulness practice or received integrative medicine therapy, including acupuncture\u002Facupressure, mindfulness or stress-reduction programs, massage, and\u002For energy therapies within the past 60 days\n* Currently taking medication for insomnia\n* An exclusionary unstable medical or mental health condition as determined by the patient's oncologist",{"count":359,"type":21},20,[249],"This early phase I trial evaluates the feasibility and impact of a meditation headband system (MUSE-S) for breast cancer survivors. Anxiety and insomnia are among the most common distresses in breast cancer survivors during and after chemotherapy, in part due to the side effects of chemotherapy, fear of cancer coming back, progression of the cancer, and uncertainty of the future. These distresses impair patients' well-being and quality of life (QOL) in general, and their cancer treatment adherence and effectiveness in particular. Meditation has been demonstrated to be an effective management tool of stress and anxiety and is given the highest level of evidence (grade A) in the systematic review-based guidelines by the Society of Integrative Medicine. The portable, interactive, electroencephalographic (EEG) Muse headband guided meditation has been shown to improve fatigue, QOL, and stress in newly diagnosed breast cancer patients. The MUSE-S Headband System may decrease anxiety and insomnia among breast cancer survivors.",[26],{"date":346,"type":38},{"date":365,"type":38},"2024-01-08",{"date":367,"type":21},"2029-01-31",{"name":211,"class":121},{"id":370,"slug":4,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":69,"phases":377,"briefSummary":378,"conditions":379,"keywords":389,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":395,"locationsCount":46},"100640818","NCT07606287","Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital","Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital","Inclusion Criteria:\n\n1. Patient records for adults aged 65 years or older\n2. Patient records with a surgical encounter or preoperative evaluation within participating James Cancer Hospital surgical oncology services during the rollout period\n3. Patient records with data available in institutional electronic health record or institutional data systems\n4. Clinical staff age 18 years or older who are employed or credentialed at The Ohio State University Wexner Medical Center and work within clinical areas affected by ACS Geriatric Surgery Verification implementation\n\nExclusion Criteria:\n\n1. Patient records for encounters occurring only at outside institutions or non-James hospitals within the enterprise\n2. Patient records missing all primary outcome fields after data quality checks\n3. Clinical staff who are trainees, including medical students, physician assistant students, nursing students, resident physicians, or fellows\n4. Clinical staff whose employment, visa, or institutional status would make participation sensitive under institutional policy, if applicable",{"count":376,"type":21},4000,[71],"This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital. The program is designed to improve surgical care for adults age 65 and older by helping care teams identify and address age-related needs before, during, and after surgery.\n\nOlder adults with cancer may have concerns related to physical function, memory or thinking, medications, social support, and goals of care. If these needs are not recognized, patients may be at higher risk for complications, longer hospital stays, readmission, or discharge to a facility instead of home.\n\nThe ACS GSV Program includes standards for geriatric surgery leadership, goals-of-care discussions, screening for age-related vulnerabilities, care plans for identified needs, age-friendly perioperative care, and regular review of surgical outcomes. This study will evaluate how well these standards are adopted across surgical oncology services and whether implementation is associated with better outcomes, such as shorter hospital stays, fewer complications, fewer readmissions, and improved discharge outcomes.\n\nThe results may help improve surgical care workflows for older adults undergoing cancer surgery.",[26,291,380,381,382,383,80,384,385,386,387,388],"Malignant Female Reproductive System Neoplasm","Malignant Genitourinary System Neoplasm","Malignant Head and Neck Neoplasm","Malignant Nervous System Neoplasm","Malignant Thoracic Neoplasm","Skin Neoplasm","Soft Tissue Neoplasm","Central Nervous System Neoplasm","Endocrine Gland Neoplasms",[390,391],"geriatric surgery verification","oncogeriatrics",{"date":328,"type":38},{"date":204,"type":21},{"date":296,"type":21},{"name":276,"class":121},{"id":397,"slug":4,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":69,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":46},"100499790","NCT05787834","Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer","Respiratory Muscle Training During Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity","Inclusion Criteria:\n\n* Documented breast cancer and scheduled to receive adjuvant or neoadjuvant chemotherapy\n* Age \\>= 21 years old\n* Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer)\n* Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation\n* Treated at Roswell Park Comprehensive Cancer Center\n\nExclusion Criteria:\n\n* Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention",{"count":403,"type":21},130,[71],"This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.",[26,407,408],"Head and Neck Cancer","Lung Cancer","2026-05-26",{"date":328,"type":38},{"date":412,"type":38},"2023-10-16",{"date":414,"type":21},"2029-10-16",{"name":416,"class":121},"Roswell Park Cancer Institute",{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":129,"enrollmentInfo":423,"targetDuration":4,"studyType":69,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":4},"100640894","NCT07605195","Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning","Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning: Multicenter Retrospective and Prospective Validation","Inclusion Criteria\n\n1. Female patients aged ≥ 18 years.\n2. Complete bilateral digital breast tomosynthesis (DBT) images available, including craniocaudal (CC) and mediolateral oblique (MLO) views.\n3. Confirmed pathological diagnosis (core needle biopsy or surgical resection) serving as the reference standard; or benign lesions with stable findings on follow-up for more than 2 years.\n4. (For the efficacy prediction subgroup) Patients who received complete neoadjuvant therapy and had postoperative pathological results.\n\n2\\. Exclusion Criteria\n\n1. Poor image quality with severe artifacts that precluded reliable analysis.\n2. History of previous breast surgery or radiotherapy (except for the recurrence risk subgroup).\n3. Incomplete clinical or pathological data.",{"count":284,"type":21},[71],"This study aims to construct a multi-task deep learning model system to mine deep features in DBT images, so as to achieve accurate detection of breast lesions, differential diagnosis of benign and malignant (especially for the challenging BI-RADS 4A category), prediction of molecular subtypes, and evaluation of neoadjuvant chemotherapy (NAC) efficacy, providing an imaging basis for precision medicine.",[26],"2026-05-19",{"date":429,"type":38},"2026-05-22",{"date":431,"type":21},"2026-05-20",{"date":90,"type":21},{"name":142,"class":121},{"id":435,"slug":4,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":64,"sex":99,"minAge":65,"maxAge":306,"enrollmentInfo":440,"targetDuration":4,"studyType":69,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":452},"100531093","NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","Phase 2 Study of Low Dose Tamoxifen +\u002F- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer","Inclusion Criteria:\n\n* Age 45 - 74\n* Postmenopausal female\n\n  * Postmenopausal is defined as either\n\n    * Prior removal of the ovaries, or if ovaries intact amenorrhea for \\>= 12 months and not on any form of contraception, or\n    * Amenorrhea for greater than 2 months with serum follicle-stimulating hormone (FSH) in postmenopausal range (\\>= 25 IU\u002FL). Women with ovaries and a prior hysterectomy or endometrial ablation \\\u003C age 55 must have a FSH \\>= 25 IU\u002FL. Women may be on vaginal low dose estrogen preparations for vaginal dryness. Women over age 50 with a levonorgestrel intrauterine device in place for 2 or more years and not planning removal in the next 6 month are also eligible if FSH \\>= 25 IU\u002FL\n\n      * Note: FSH will be done at time of screening\n* Women with intact ovaries and uterus \\\u003C age 55 must have a negative pregnancy test prior to randomization\n* Overweight or obese (body mass index \\[BMI\\] \\>= 25 kg\u002Fm\\^2)\n\n  * Note: BMI must be calculated within 28 days of randomization\n* Willing to undergo a fasting blood draw and non-fasting RPFNA with fixed and frozen aliquots sent to University of Kansas Medical Center (KUMC)\n* At increased risk of breast cancer per at least one of the following:\n\n  * Personal medical history\n\n    * History of atypical hyperplasia or lobular carcinoma in situ (LCIS) found on breast biopsy\n    * History of unilateral ductal carcinoma in situ treated with unilateral mastectomy, lumpectomy, or local excision with or without radiation and this treatment was completed at least 3 months prior to the screening RPFNA\n    * High mammographic density determined by one of the following:\n\n      * Visual estimate of area of density (VAS) \\> 50%,\n      * Volpara (trademark) \\>= 15% dense volume (Volpara d)\n      * Breast Imaging Reporting and Data System (BIRADS) assessment = extremely dense (BIRADs D)\n  * Genetic test result\n\n    * Germline gene mutation in ATM, BARD1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, or STK11\n    * Polygenic lifetime risk score \\>= 2x average or 25%\n  * Calculated risk based on standard models\n\n    * Five-year Breast Cancer Risk Assessment Tool (BCRAT) (version 2.0) \\>= 1.66%\n    * Ten-year International Breast Cancer Intervention Study risk evaluation tool (IBIS) (version 8) \\>= 3%\n    * Ten-year relative risk IBIS (version 8) \\>= 2X that for age group\n    * Ten- year Breast Cancer Surveillance Consortium (version 2) \\>= 3%\n  * Family History\n\n    * Breast cancer in a first or second degree relative (female or male) with onset under age 50. (First degree relative = parent, sibling, or child. Second degree relative = grandparent, uncle, aunt, nephew, niece, half-sibling, grandchild or first cousin)\n    * Breast cancer in two or more first or second-degree relatives from either the maternal or paternal linage without regard to age\n    * Bilateral breast cancer or breast and ovarian cancer in the same first or second degree relative without regard to age\n  * Primary source documentation of risk is required and must be submitted to the lead academic organization (LAO) for review along with the eligibility checklist\n\n    * Risk factor: Atypical hyperplasia or LCIS; Primary source document: Copy of pathology report or clinical note confirming the diagnosis\n    * Risk factor: Ductal carcinoma in situ (DCIS) and treatment history; Primary source document: Copies of pathology report or clinic notes confirming the diagnosis, treatment plan and treatment end date(s)\n    * Risk factor: Mammographic density; Primary source document: Copy of clinic note or mammogram report\n    * Risk factor: Genetic; Primary source document: Copy of genetic test report\n    * Risk factor: Calculated based on standard models; Primary source document: Copy of the calculation result\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN)\n\n  * Note: Higher total bilirubin levels (=\\\u003C 3 mg\u002FdL) can be allowed if due to known benign liver condition, i.e., Gilbert's syndrome\n  * Results from prior laboratory testing within 180 days of randomization may be used\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) =\\\u003C 3.0 x institutional upper limit of normal\n\n  * Results from prior laboratory testing within 180 days of randomization may be used\n* Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3.0 x institutional upper limit of normal\n\n  * Results from prior laboratory testing within 180 days of randomization may be used\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Women must have at least 1 unaffected untreated breast for fine needle aspiration. Women may have had prior unilateral breast radiation or mastectomy for DCIS\n* Ability to understand and the willingness to sign a written informed consent document\n* Most recent screening mammogram must be performed ≤ 12 months prior to RPFNA and must be reported as BIRAD 1 or 2. If BIRAD 0 then follow-up diagnostic imaging must be BIRAD 1 or 2 or cleared clinically with radiology recommendation of return to annual screening\n* Confirmation that baseline research blood was drawn fasting (\\>= 10 hours), has been received in good condition at KUMC, and is archived for assessment of primary endpoint\n\nExclusion Criteria:\n\n* Exclusions based on current or past conditions:\n\n  * Bilateral breast implants (danger of implant puncture with RPFNA)\n  * Prior invasive breast cancer\n  * Prior invasive uterine cancer\n  * Other prior invasive cancer and haven't completed cancer related therapy or with evidence of disease (other than non-melanoma skin cancer) within the past 2 years\n  * Currently breastfeeding (concern that tamoxifen may be in breast milk) or nursing within past 12 months (concern about milk fistula with RPFNA)\n  * Type I or type II diabetes mellitus requiring current pharmacologic treatment (including metformin, glucagon-like peptide 1 agonists, insulin, sulfonylurea)\n  * Prior deep vein thrombosis, pulmonary embolus, or stroke\n  * Prior gastric bypass surgery\n  * History of chronic liver disease including NASH (nonalcoholic steatohepatitis) or cirrhosis\n  * Pathogenic or likely pathogenic germline mutation in BRCA1 or TP53\n* Exclusions based on medications:\n\n  * Current use of prescription anticoagulants such as Coumadin (warfarin), direct-acting oral anticoagulants such as Xarelto (rivaroxaban) or Eliquis (apixaban) or heparin\n  * Women who would not be able to or do not wish to discontinue daily use of aspirin (81mg or higher) and aspirin containing products (81 mg or higher) at least 3 weeks prior to each RPFNA\n\n    * Note: Women may resume daily use of aspirin and aspirin containing products 3 days after each RPFNA procedure\n  * Current use of a levonorgestrel intrauterine device if in place less than 2 years or if there is planned removal within the next 6 months\n  * Current use of hormone therapy (oral, transdermal, or injectable)\n\n    * Note: Vaginal estrogen is allowed\n  * Prior treatment with tamoxifen, aromatase inhibitor or selective estrogen receptor degrader for more than 2 months\n\n    * Note: Women with \\\u003C 2 months of these drugs must be off for at least 6 months before they may begin biomarker screening tests\n  * Greater than 1 gram daily of omega-3 fatty acid supplement within the last 6 months\n  * Current use of prescription immunosuppressive drugs\n  * Current use of CYP3A4 strong inducers rifampin or aminoglutethimide\n  * Current use of or plans to initiate a glucagon-like peptide 1 agonist within the next 6 months\n  * Current use of metformin for any indication\n* Participants may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen or omega-3 fatty acid or generic Lovaza or compounds of similar chemical composition\n* Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":441,"type":21},66,[103],"This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.",[445,26,157,158],"Breast Atypical Hyperplasia",{"date":431,"type":38},{"date":448,"type":38},"2025-07-28",{"date":450,"type":21},"2028-01-01",{"name":44,"class":45},3,{"id":454,"slug":4,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":69,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":46},"100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":460,"type":21},27,[103],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[464,465,466,74,26,467,75,468,469,470,471,288,472,473,474,79,80,475,476,477,478,479,81,82,480,83,481,482,483],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Primary Peritoneal Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":486,"type":38},"2026-05-18",{"date":488,"type":38},"2025-12-18",{"date":490,"type":21},"2026-12-18",{"name":211,"class":121},{"id":493,"slug":4,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":99,"minAge":498,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":69,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":512},"100511598","NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer","Inclusion Criteria:\n\n* Age \\>= 35 years\n* Considered clinically premenopausal\n* Having regular menstrual cycles (between 21 and 35 days) unless a contraceptive device such as progestin containing intrauterine device (IUD) (e.g., Mirena IUD) is being used which suppresses menstrual periods, or premenopausal women who have undergone a hysterectomy, but ovaries are intact\n* Not considering pregnancy for at least 12 months\n* Women of child-bearing potential capacity must be willing to have used effective birth control precautions for 8 weeks prior to fine needle aspiration and be willing to continue for 8 weeks after study completion as tamoxifen may have teratogenic effects on the developing fetus. Reproductive and developmental toxicity studies have not been conducted with acolbifene. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must stop study drug and inform her study physician immediately.\n\n  * For women not using oral contraceptive (progestin alone or estrogen plus a progestin), two of the following are recommended but woman must agree to at least one of the following methods:\n\n    * IUD non-hormonal or hormone containing (usually a progestin) intrauterine device (IUD) or rings. Any of these should have been inserted at least 8 weeks prior to RPFNA.\n    * Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide)\n    * Partner has had a vasectomy.\n  * For women using oral contraceptive (progestin alone or estrogen plus a progestin), woman must agree to at least a non- hormonal IUD or a barrier method (below) or her partner must have had a vasectomy:\n\n    * Non-hormonal IUD\n    * Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide)\n    * Partner has had a vasectomy\n* Must have increased breast cancer risk as predicted by any one or more of the conditions listed below or increased model calculated risk as below:\n\n  * Any one or more of the following conditions associated with increased risk (condition must be documented in electronic medical record or copy of relevant pathology or genetic testing reports submitted with the eligibility checklist)\n\n    * A prior biopsy at any time in the past showing ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical hyperplasia. (If DCIS must have been treated by mastectomy or local excision +\u002F- radiation with this treatment completed at least 3 months prior to screening with RPFNA)\n    * High or moderate penetrance risk pathogenic or likely pathogenic germline gene mutation in ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, or TP53\n    * High polygenic risk score (Life-time risk of \\>= 2x average or 25%)\n    * Breast cancer in a first or second degree relative (female or male) with onset under age 50. First degree relative is defined as parent, sibling, or child. Second degree relative is defined as grandparent, uncle, aunt, nephew, niece, half-sibling, grandchild or first cousin\n    * Two or more affected first or second-degree relatives from either the maternal or paternal lineage without regard to age\n    * Bilateral breast cancer or breast and ovarian cancer in the same first or second degree relative without regard to age.\n    * High mammographic density defined as either visual estimate of area of density (VAS) \\> 50%, or Volpara (Trademark) \\>= 15% dense volume (Volpara d) or Breast Imaging Reporting and Data System (BIRADS) assessment of extremely dense (BIRADs D)\n  * Alternatively, instead of conditions listed above, an increased risk of breast cancer as calculated by International Breast Cancer Intervention Study Version 8 (IBIS 8), or Breast Cancer Surveillance Consortium (BCSC) 3 by one or more of the following criteria:\n\n    * 10-year risk of breast cancer of \\>= 3%\n    * Increase in age specific 10-year relative risk by age group\n\n      * Age 35-39 10-year relative risk of \\>= 5X that for age group\n      * Age 40-44 10-year risk of \\>= 4X that for age group\n      * Age 45 and up 10-year risk of \\>= 2X\n    * IBIS Version 8 Remaining lifetime risk of \\>= 25% or \\>= 2X that of population\n  * A copy of the output of model calculations from IBIS 8 (https:\u002F\u002Fems-trials.org\u002Friskevaluator\u002F), or BCSC version 3.0 (https:\u002F\u002Ftools.bcsc-scc.org\u002FBC5yearRisk\u002Fcalculator.htm) online tools, if used for qualifying risk assessment, or polygenetic risk score should be submitted with the eligibility checklist. Otherwise, these risk qualifying factors need to be documented in the medical record if that is considered the source document\n* Women must have at least 1 unaffected untreated breast for fine needle aspiration. Women may have had prior unilateral breast radiation or mastectomy for DCIS\n* Eastern Cooperative Oncology Group (ECOG) current performance status (PS) ≤ 2 as documented within 3 months prior to randomization or Karnofsky score \\>= 60%\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) =\\\u003C 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization)\n* Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization)\n* Creatinine =\\\u003C 2.0 mg\u002FdL (measured within 180 days prior to randomization)\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Bilateral breast implants (danger of implant puncture with RPFNA)\n* Women who are pregnant\n* Currently breastfeeding (concern that tamoxifen or acolbifene may be in breast milk) or nursing within the past 12 months (concern about milk fistula with RPFNA)\n* Prior invasive breast cancer within the past 5 years\n* Other prior invasive cancer \\> T1 stage (other than non-melanoma skin) within the past 5 years\n* Pathogenic or likely pathogenic germline mutation in BRCA1\u002F2 or PALB2 (These latter individuals are likely to undergo yearly ovarian screening and enlarging cysts could raise concern about ovarian cancer and lead to unnecessary diagnostic procedures)\n* Type I or Type II diabetes mellitus requiring treatment with prescription medication\n* Prior deep vein thrombosis, pulmonary embolus, or stroke\n* History of chronic liver disease including NASH (nonalcoholic steatohepatitis) and chronic hepatitis C\n* History of chronic hepatitis B or hepatitis C (danger of exacerbation of liver damage from hepatitis or tamoxifen-induced non-alcoholic fatty liver disease or non-alcoholic steatohepatitis)\n* History of human immunodeficiency virus (HIV)-infection (danger of exacerbation of underlying clinically inapparent liver damage caused by HIV and\u002For hepatotoxicity can be induced by interaction of tamoxifen-induced CYP3A4 with direct anti-hepatitis C virus \\[HCV\\] agents)\n* Current use of prescription anticoagulants such as Coumadin (warfarin), direct-acting oral anticoagulants such as Xarelto (rivaroxaban) or Eliquis (apixaban), or heparin\n* Women who would not be able to or do not wish to discontinue daily use of aspirin (81 mg or higher) and aspirin containing products (81 mg or higher) at least 3 weeks prior to each RPFNA are not eligible. Women who would be able to stop daily use of aspirin and aspirin containing products at least 3 weeks prior to each RPFNA are eligible\n\n  * NOTE: Women may resume daily use of aspirin and aspirin containing products 3 days after each RPFNA procedure\n* Starting or stopping oral contraceptives (OCs) or hormonal progestin IUDs within 8 weeks of baseline RPFNA\n* Current use or use within the prior 8 weeks of progesterone\u002Fprogestin injections or progestin implants (due to concerns about high levels of progestin and lack of safety and efficacy data with low dose tamoxifen)\n* Current use of other investigational agents\n* Prior treatment with acolbifene for more than 2 months\n* Prior treatment with tamoxifen for more than 2 months\n* Current use of prescription immunosuppressive drugs\n* History of allergic reactions attributed to tamoxifen or acolbifene or compounds of similar chemical composition\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study","35 Years",{"count":500,"type":21},80,[103],"This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast cancer is to undergo yearly breast magnetic resonance imaging or ultrasound in addition to yearly mammogram. Premenopausal women at very high lifetime risk for breast cancer (greater than 50%) can consider preventive removal (mastectomy) of both breasts. Premenopausal women age 35 or older with a prior diagnosis of atypical hyperplasia, lobular carcinoma in situ, or an estimated 10-year risk of greater than or equal to 3% or estimated 10-year risk of greater than or equal to 2-5 times that of the average woman (depending on age) may be advised to consider five years of standard dose tamoxifen. Standard dose tamoxifen is four times the dose used in this study. Estrogen can cause the development and growth of breast cancer cells. Acolbifene and tamoxifen blocks the use of estrogen by breast cells. This study may help researchers measure the effects of acolbifene and low dose tamoxifen on markers of breast cancer risk in mammogram imaging, breast tissue, and in blood samples.",[445,26,157,158],"2026-05-12",{"date":506,"type":38},"2026-05-13",{"date":508,"type":38},"2024-08-23",{"date":510,"type":21},"2028-09-01",{"name":44,"class":45},4,{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":46},"100470467","NCT05406232","Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer","Breast Radiation-induced Immunologic Genomic Hypofractionated Temporal Radiation Alterations DNA Damage (BRIGHT-RAD) Study.","Inclusion Criteria:\n\n* Patients \\>= 18 years of age with biopsy proven invasive breast cancer\n* Breast cancer that appears to be superficially accessible to a tumor punch biopsy\n* Patients thought to derive clinical benefit from palliative RT to the breast\u002Fchestwall\n* In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT\n\nExclusion Criteria:\n\n* A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered\n* Pregnancy\n* Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies\n* Receipt of immunotherapy or chemotherapy 7 days prior to start of RT",{"count":520,"type":21},36,"This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.",[26,523],"Invasive Breast Carcinoma","2026-04-30",{"date":526,"type":38},"2026-05-06",{"date":528,"type":38},"2023-09-15",{"date":530,"type":21},"2026-12-31",{"name":298,"class":121},{"id":533,"slug":4,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":64,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":46},"100443626","NCT05056857","Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen","Neutrophil Functions in Breast Cancer","Inclusion Criteria:\n\n* Female\n* Age criteria for pre-menopausal group: Equal to or greater than 18 years of age and less than or equal to 45 years of age. Patients of age 46-50 will be included if they have not had menstrual cessation for 12 consecutive months.\n* Age criteria for menopausal group: At least 51 years of age (median age of menopause). Menopause is defined as cessation of menstrual cycle for 12 consecutive months.\n* Diagnosed with ER+ breast cancer\n* Being treated with tamoxifen (TAM) for at least 6 months\n* CONTROL SUBJECTS: Newly diagnosed ER+ breast cancer patients of the same age group as above on TAM for 0-6 months. This criterion is based on our preliminary results showing that patients taking TAM for 6-7 months exhibit near baseline level of NETs\n\nExclusion Criteria:\n\n* Pregnant -The immune modulations geared toward maintenance of pregnancy are known to cause wide-spread alterations in innate and adaptive immune cell functions. In this scenario, divorcing the pregnancy-related changes in myeloid cell function from those relevant to sepsis and cancer will be complicated.\n* History of severe congenital neutropenia due to genetic disorders, such as Kostmann Disorder (HAX1 gene mutation), ELA2 gene mutation, Wiskott-Aldrich syndrome (WAS), Growth Factor Independent 1 Protein (GFI1) gene mutation, Colony Stimulating Factor 3 Receptor (CSF3R) gene mutation, Schwachman-Diamond Syndrome, Barth Syndrome, WHIM Syndrome, and Chadiak-Higashi Syndrome (this list notably does not include Myelodysplastic Syndrome, or Acute\u002FChronic Myeloid Leukemia)\n* History of autoimmune disorders, which can affect the body's inflammatory response, such as rheumatoid arthritis, lupus, Crohn's disease, multiple sclerosis, and psoriasis.\n* History of chronic viral infections (human immunodeficiency virus \\[HIV\\], hepatitis), which can lead to reduced or variable immune cell function.\n* A recent positive coronavirus disease (COVID) test",{"count":539,"type":21},290,"This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system. Treatment with tamoxifen increases the production of NETs. This study may help researchers determine if the increased number of NETs in the body has a damaging effect in breast cancer.",[26],"2026-04-29",{"date":544,"type":38},"2026-05-01",{"date":546,"type":38},"2021-10-01",{"date":548,"type":21},"2026-10-31",{"name":298,"class":121},{"id":551,"slug":4,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100486286","NCT05612100","Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients","Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Women with a diagnosis of breast cancer who are being treated with curative intent, with the one exception being women who are receiving CDK4\u002F6 inhibitors (these patients being allowed to have more advanced disease)\n* Provide informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Filling into one of the 5 groups (understanding that groups will close once they complete their accrual goals of 30 patients)\n* Willingness to complete questionnaires every 3 months\n* Ability to complete the first questionnaire within 2 weeks of therapy initiation (for the four arms that are receiving adjuvant hormonal therapy)\n\n  * For patients starting tamoxifen or an aromatase inhibitor: within 2 weeks of starting tamoxifen or aromatase inhibitor\n  * For patients starting a CDK 4\u002F6 inhibitor: within 2 weeks of starting the CDK 4\u002F6 inhibitor (patients may have started an aromatase inhibitor at any time prior to initiation of CDK 4\u002F6 inhibitor).\n\nExclusion Criteria:\n\n* Verbal baseline alopecia \\>= 2 on an 11 point scale (from none = 0 to severe = 10). The question to use for this item is: Please rate your hair thinning or loss on a scale from 0 to 10, with 0 being no hair loss and 10 being complete hair loss\n* Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g., everolimus, etc.; note that a CDK4\u002F6 inhibitor is allowed within cohort 3)\n* Prior use of endocrine therapy for breast cancer\n* Receipt of chemotherapy over the previous 6 months",{"count":557,"type":21},170,"This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.",[26],"2026-04-28",{"date":524,"type":38},{"date":563,"type":38},"2022-07-06",{"date":565,"type":21},"2028-06-30",{"name":211,"class":121},23,""]